[go: up one dir, main page]

EP1818059A4 - AGENT FOR THE PREVENTION OR TREATMENT OF GLAUCOMA - Google Patents

AGENT FOR THE PREVENTION OR TREATMENT OF GLAUCOMA

Info

Publication number
EP1818059A4
EP1818059A4 EP05819681A EP05819681A EP1818059A4 EP 1818059 A4 EP1818059 A4 EP 1818059A4 EP 05819681 A EP05819681 A EP 05819681A EP 05819681 A EP05819681 A EP 05819681A EP 1818059 A4 EP1818059 A4 EP 1818059A4
Authority
EP
European Patent Office
Prior art keywords
glaucoma
agent
prevention
treatment
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05819681A
Other languages
German (de)
French (fr)
Other versions
EP1818059A1 (en
EP1818059B1 (en
Inventor
Makoto Kanebako
Masatoshi Takahashi
Ken Mizuno
Shin Sugimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Priority to PL05819681T priority Critical patent/PL1818059T3/en
Priority to SI200530540T priority patent/SI1818059T1/en
Publication of EP1818059A1 publication Critical patent/EP1818059A1/en
Publication of EP1818059A4 publication Critical patent/EP1818059A4/en
Application granted granted Critical
Publication of EP1818059B1 publication Critical patent/EP1818059B1/en
Priority to CY20081101444T priority patent/CY1108651T1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A preventing or treating agent for glaucoma or ocular hypertension is provided. This drug has a strong action of reducing intraocularpressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops comprising (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.
EP05819681A 2004-12-23 2005-12-22 Preventive or therapeutic agent for glaucoma Expired - Lifetime EP1818059B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL05819681T PL1818059T3 (en) 2004-12-23 2005-12-22 Preventive or therapeutic agent for glaucoma
SI200530540T SI1818059T1 (en) 2004-12-23 2005-12-22 Preventive or therapeutic agent for glaucoma
CY20081101444T CY1108651T1 (en) 2004-12-23 2008-12-11 Preventative or therapeutic agents for glaucoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63811804P 2004-12-23 2004-12-23
PCT/JP2005/023570 WO2006068208A1 (en) 2004-12-23 2005-12-22 Preventive or therapeutic agent for glaucoma

Publications (3)

Publication Number Publication Date
EP1818059A1 EP1818059A1 (en) 2007-08-15
EP1818059A4 true EP1818059A4 (en) 2007-12-26
EP1818059B1 EP1818059B1 (en) 2008-12-03

Family

ID=36601805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05819681A Expired - Lifetime EP1818059B1 (en) 2004-12-23 2005-12-22 Preventive or therapeutic agent for glaucoma

Country Status (23)

Country Link
EP (1) EP1818059B1 (en)
JP (1) JP4099201B2 (en)
KR (1) KR101286813B1 (en)
CN (1) CN101087613B (en)
AT (1) ATE415972T1 (en)
AU (1) AU2005320085B2 (en)
BR (1) BRPI0519007A2 (en)
CA (1) CA2585372A1 (en)
CY (1) CY1108651T1 (en)
DE (1) DE602005011476D1 (en)
DK (1) DK1818059T3 (en)
EA (1) EA011085B1 (en)
ES (1) ES2317338T3 (en)
MX (1) MX2007007614A (en)
MY (1) MY138811A (en)
NO (1) NO20072187L (en)
NZ (1) NZ555137A (en)
PL (1) PL1818059T3 (en)
PT (1) PT1818059E (en)
SI (1) SI1818059T1 (en)
TW (1) TWI367098B (en)
WO (1) WO2006068208A1 (en)
ZA (1) ZA200704874B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007879A1 (en) * 2005-07-14 2007-01-18 Sharp Kabushiki Kaisha Display element and electronic apparatus using same
KR20110022686A (en) 2008-07-25 2011-03-07 아사히 가세이 파마 가부시키가이샤 Stable Aqueous Composition Containing Sulfonamide Compounds
TW202446398A (en) * 2011-02-04 2024-12-01 日商興和股份有限公司 Drugs that reduce intraocular pressure
EA026904B1 (en) * 2012-11-23 2017-05-31 Игорь Михайлович Юхт Method for quantitative determination of polyhexamethylene biguanidine (phmb) hydrochloride in compositions for preparing liquid medicinal products for treatment of eye and nose diseases (2 embodiments)
US20160339018A1 (en) 2013-04-24 2016-11-24 Kyushu University, National University Corporation Therapeutic agent for ocular fundus disease
PT3199160T (en) * 2014-09-25 2020-04-08 Kowa Co Aqueous composition
ES2909876T3 (en) * 2014-09-25 2022-05-10 Kowa Co pharmaceutical product
CN107106571B (en) 2014-12-12 2021-02-05 兴和株式会社 Aqueous composition
TWI699205B (en) * 2014-12-12 2020-07-21 日商興和股份有限公司 Drug therapy used to prevent or treat glaucoma
KR20160108121A (en) 2015-03-06 2016-09-19 코와 가부시키가이샤 Aqueous composition
JP2018118905A (en) * 2015-04-27 2018-08-02 恵 本庄 Preventive and therapeutic agent for post-cataract complications
CN106310285A (en) * 2015-06-15 2017-01-11 江苏吉贝尔药业股份有限公司 New ripasudil hydrochloride hydrate eye drop and preparation method thereof
JP6886322B2 (en) * 2016-03-25 2021-06-16 興和株式会社 Ophthalmic composition
CN107164328A (en) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 A kind of method for resuscitation of the breast cancer cells of high stability MCF 7
EP4338751B1 (en) 2017-12-21 2025-09-03 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
JP2020193174A (en) * 2019-05-29 2020-12-03 興和株式会社 Aqueous composition
TW202237083A (en) 2021-01-11 2022-10-01 美商英塞特公司 Combination therapy comprising jak pathway inhibitor and rock inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023222A1 (en) * 1995-12-21 1997-07-03 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401108D0 (en) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
DE19512639A1 (en) * 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitriles and fluorides
JPH10310576A (en) * 1997-03-10 1998-11-24 Hiroyoshi Hidaka Isoquinoline sulfone amide derivative and drug containing the same as an active ingredient
CZ299633B6 (en) * 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinones, intermediates for their preparation and pharmaceutical and veterinary compositions based thereon
FR2777189B1 (en) 1998-04-09 2001-04-06 Chauvin Lab Sa OPHTHALMIC COMPOSITION COMPRISING A BETA-BLOCKER
CA2327276A1 (en) * 1998-04-23 1999-10-28 Hiroshi Muramatsu Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
JP4212149B2 (en) * 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 Medicine
US6673812B1 (en) 1998-08-17 2004-01-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
EP1123274B1 (en) * 1998-10-22 2004-12-29 Neurosearch A/S Substituted phenyl derivatives, their preparation and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023222A1 (en) * 1995-12-21 1997-07-03 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
JP2001509780A (en) * 1995-12-21 2001-07-24 アルコン ラボラトリーズ，インコーポレイテッド Use of certain isoquinoline sulfonyl compounds for the treatment of glaucoma and ocular ischemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SASAKI YASUHARU ET AL: "The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-((4-me thyl-5-isoquinoline)sulfonyl)-homopiperazine as a probing molecule for Rho-kinase-involved pathway", PHARMACOLOGY AND THERAPEUTICS, vol. 93, no. 2-3, February 2002 (2002-02-01), pages 225 - 232, XP002458450, ISSN: 0163-7258 *

Also Published As

Publication number Publication date
JPWO2006068208A1 (en) 2008-06-12
MX2007007614A (en) 2007-08-15
MY138811A (en) 2009-07-31
NO20072187L (en) 2007-07-13
TW200628160A (en) 2006-08-16
PL1818059T3 (en) 2009-05-29
EA011085B1 (en) 2008-12-30
CY1108651T1 (en) 2014-04-09
HK1113312A1 (en) 2008-10-03
KR101286813B1 (en) 2013-07-17
JP4099201B2 (en) 2008-06-11
PT1818059E (en) 2008-12-31
ES2317338T3 (en) 2009-04-16
CN101087613A (en) 2007-12-12
BRPI0519007A2 (en) 2008-12-23
CN101087613B (en) 2010-08-18
EA200701134A1 (en) 2007-10-26
TWI367098B (en) 2012-07-01
NZ555137A (en) 2009-10-30
DE602005011476D1 (en) 2009-01-15
WO2006068208A1 (en) 2006-06-29
DK1818059T3 (en) 2009-03-16
AU2005320085A1 (en) 2006-06-29
EP1818059A1 (en) 2007-08-15
ATE415972T1 (en) 2008-12-15
AU2005320085B2 (en) 2010-07-29
CA2585372A1 (en) 2006-06-29
KR20070090897A (en) 2007-09-06
EP1818059B1 (en) 2008-12-03
ZA200704874B (en) 2008-08-27
SI1818059T1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
CY1108651T1 (en) Preventative or therapeutic agents for glaucoma
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2006066103A3 (en) Ophthalmic implant for treatment of glaucoma
ATE480240T1 (en) COMPOSITION CONTAINING LATANOPROST AND METHOD OF TREATMENT OF INCREASED EYE PRESSURE AND GLAUCOMA
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
ATE529102T1 (en) COMPOUND FOR PREVENTING AND TREATING GLAUCOMA
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
CY1108490T1 (en) Statins for the treatment of ocular hypertension and glaucoma
ATE359794T1 (en) 3, 7 THIAPROSTANIC ACID DERIVATIVES AS AN AGENT FOR REDUCING INTERNAL EYE PRESSURE
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
MX2008015976A (en) Topical treatment for diseases of eye surface.
WO2023147513A3 (en) Compositions of autophagy modulating agents and uses thereof
EP1482922A4 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
EP1752158A4 (en) CORNEAL NEURITOGENESIS PROMOTER CONTAINING PACAP AND ITS DERIVATIVE
MXPA04001255A (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma.
UA94938C2 (en) Ophthalmic compositions for treating a clinical symptom of ocular allergy comprising akaftadine or a pharmaceutically acceptable salt thereof
WO2002015942A8 (en) Method for the identification of agents that inhibit or promote cataracts and uses thereof
RU2007119978A (en) METHOD FOR TREATING GLAUCOMA IN THE TERMINAL STAGE OF DISEASE
UA86346C2 (en) Method for treatment of open-angle glaucoma
WO2004087051A3 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20071128

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KANEBAKO, MAKOTO

Inventor name: SUGIMOTO, SHIN

Inventor name: MIZUNO, KEN

Inventor name: TAKAHASHI, MASATOSHI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SUGIMOTO, SHIN

Inventor name: KANEBAKO, MAKOTO

Inventor name: MIZUNO, KEN

Inventor name: TAKAHASHI, MASATOSHI

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20081218

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005011476

Country of ref document: DE

Date of ref document: 20090115

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090400041

Country of ref document: GR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E002866

Country of ref document: EE

Effective date: 20090218

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2317338

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E005522

Country of ref document: HU

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20090923

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090923

26N No opposition filed

Effective date: 20090904

REG Reference to a national code

Ref country code: PT

Ref legal event code: NF4A

Free format text: RESTITUTIO IN INTEGRUM

Effective date: 20091207

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: PT

Effective date: 20091207

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: KOWA COMPANY, LTD.

Free format text: KOWA COMPANY, LTD.#6-29, NISHIKI 3-CHOME#NAKA-KU NAGOYA-SHI, AICHI-KEN 460-8625 (JP) -TRANSFER TO- KOWA COMPANY, LTD.#6-29, NISHIKI 3-CHOME#NAKA-KU NAGOYA-SHI, AICHI-KEN 460-8625 (JP)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20141215

Year of fee payment: 10

Ref country code: EE

Payment date: 20141219

Year of fee payment: 10

Ref country code: LT

Payment date: 20141211

Year of fee payment: 10

Ref country code: FI

Payment date: 20141215

Year of fee payment: 10

Ref country code: SK

Payment date: 20141212

Year of fee payment: 10

Ref country code: RO

Payment date: 20141212

Year of fee payment: 10

Ref country code: MC

Payment date: 20141216

Year of fee payment: 10

Ref country code: CZ

Payment date: 20141212

Year of fee payment: 10

Ref country code: BG

Payment date: 20141229

Year of fee payment: 10

Ref country code: IE

Payment date: 20141212

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20141215

Year of fee payment: 10

Ref country code: HU

Payment date: 20141216

Year of fee payment: 10

Ref country code: SI

Payment date: 20141210

Year of fee payment: 10

Ref country code: LV

Payment date: 20141223

Year of fee payment: 10

Ref country code: IS

Payment date: 20141217

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20141216

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20151222

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20151231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E002866

Country of ref document: EE

Effective date: 20151231

Ref country code: AT

Ref legal event code: MM01

Ref document number: 415972

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160630

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 4666

Country of ref document: SK

Effective date: 20151222

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20160830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151223

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151223

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20181219

Year of fee payment: 14

Ref country code: PL

Payment date: 20181214

Year of fee payment: 14

Ref country code: LU

Payment date: 20181217

Year of fee payment: 14

Ref country code: PT

Payment date: 20181218

Year of fee payment: 14

Ref country code: NL

Payment date: 20181217

Year of fee payment: 14

Ref country code: GR

Payment date: 20181219

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20181217

Year of fee payment: 14

Ref country code: CH

Payment date: 20181219

Year of fee payment: 14

Ref country code: FR

Payment date: 20181218

Year of fee payment: 14

Ref country code: GB

Payment date: 20181219

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181221

Year of fee payment: 14

Ref country code: IT

Payment date: 20181227

Year of fee payment: 14

Ref country code: ES

Payment date: 20190121

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20190115

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005011476

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20200101

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191231

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200707

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191222

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200701

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191222

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191223

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191222

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191223

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191222